To date, clinical anti-angiogenic therapies for invasive PAs include bevacizumab, an anti-VEGF-A monoclonal antibody, and anti-tyrosine kinase inhibitors Sunitinib (which primarily targets VEGFR1 and VEGFR2) and Apatinib (which primarily targets VEGFR2) (Fig. 2D). This evidence concerns the gene KDR and gonorrhea.